Contributed Commentary by Farrell Healion, OptiTrial 

March 13, 2026 | Clinical Operations is entering a phase where the hype around artificial intelligence (AI) and digital transformation is giving way to something more meaningful. For the last decade, much of the industry’s effort has focused on layering new technologies onto existing processes. By 2030, that approach will no longer be enough. The real opportunity is to rethink what clinical trial work should look like when data, systems, and workflows do the heavy lifting, freeing people to focus on the parts of research that truly require human judgement and connection. 

The first visible shift is already underway. Clinical trials are becoming more digital and more data driven but not simply through added devices or dashboards. The real change is that data is beginning to flow continuously across the trial lifecycle rather than being collected, cleaned, and reviewed in silos. As interoperability improves, trials will increasingly be designed around the intelligent reuse of data rather than repeated manual entry, reducing friction for sites and study teams. 

One practical example is screening and eligibility. Today, sites often re-enter information that already exists in electronic health records, then reconcile it again during monitoring. By 2030, where regulations and infrastructure allow, structured electronic health record (EHR) data will increasingly be pulled directly into study systems to support pre-screening, flag eligibility criteria, and accelerate recruitment. Human oversight remains essential, but effort shifts away from transcription toward clinical decision-making, patient conversations, and operational judgement. 

Risk-based quality management will also look fundamentally different. Risk-based quality management (RBQM) has long promised smarter oversight, but its real potential is only unlocked when high-quality digital data is available early and continuously. By 2030, agentic AI operating in the background will increasingly monitor data streams against critical-to-quality elements, proactively flagging emerging risks and patterns that warrant attention. Instead of waiting for issues to surface during periodic review cycles, teams can act on early signals before they escalate into larger problems. 

This evolution directly reshapes the role of the clinical research associate (CRA). Monitoring will be far less defined by exhaustive data review and far more by insight-driven action. As agents handle much of the routine data review, signal detection, and trend analysis, CRAs are freed from a significant administrative burden. Their role shifts toward strengthening site relationships, supporting recruitment and retention, and resolving issues through collaboration rather than inspection. By 2030, the most effective monitors will be those who combine data literacy with strong interpersonal skills and a deep understanding of site realities. 

Connected data capture will also extend well beyond today’s bring-your-own-device (BYOD) models. BYOD has shown that participants are more engaged when studies fit naturally into their lives. The next step is enabling bring-your-own-wearable approaches where scientifically appropriate. The accuracy gap between consumer-grade and clinical-grade technologies continues to narrow, and in many cases the risk-benefit balance will tip in favour of using devices participants already own and trust. This reduces the cost of inclusion, avoids issuing redundant hardware, improves sustainability, and removes friction for participants who would otherwise be asked to manage multiple devices. 

Even in a more connected ecosystem, no dataset will ever be complete. This is where synthetic data may begin to play a complementary role. Used responsibly, synthetic data can help explore variability, address gaps, and support scenario modelling without exposing patient privacy. It is not a substitute for real-world data, but it may become an important tool for operational planning and trial design as governance and methodologies mature. 

Another important shift will be how digital therapeutics and medicines are studied together. Rather than evaluating a drug in isolation, future trials may increasingly assess pharmaceutical treatments alongside digital interventions that support adherence, behaviour change, or symptom management. For Clinical Operations teams, this introduces new considerations around coordination, data integration, and oversight, requiring closer alignment between clinical, technical, and operational functions. 

All of this points to a future where the work of Clinical Operations looks fundamentally different from today. Fewer hours will be spent reconciling data across disconnected systems. Less energy will be consumed by manual handoffs and administrative workarounds. More time will be available for thoughtful study design, meaningful site partnerships, and patient support. 

Getting there will require more than adopting new technology. It will demand redesigning rigid processes so that they fully benefit from what technology enables. Rather than digitizing existing manual workflows, organizations will need to rethink how work is done when AI agents act as virtual coworkers, handling data review, triage, and routine tasks in the background. True adoption happens when processes evolve alongside technology. 

Clinical Operations in 2030 will not be defined by any single platform or breakthrough. It will be defined by how effectively data and workflows carry the operational load, so that human expertise can be applied where it matters most. If the industry gets this right, we will be optimizing trials for the people that matter most: patients, sites, and the teams running them. 

Farrell Healion is the Founder and Principal Consultant of OptiTrial, where he works with sponsors and study teams to design and deliver smarter, more connected clinical trials. With over 13 years of experience across sponsor and clinical technology roles, he has led global deliveries including eCOA, eConsent, remote monitoring, and AI-enabled clinical operations. Farrell is known for championing better trials for patients and better tools for sites, taking a practical, human-centred approach to clinical technology implementation. He is an award-winning thought leader with a strong focus on human-centric, data-driven clinical operations. He can be reached at farrell@optitrial.ai.